StockWatch
·

Syndax Pharmaceuticals Inc Q2 FY26 Results

SNDXQ2 FY26 Results
Filing
MetricValue ($ M)Q1 FY26Q2 FY25
Revenue72.7912.2%91.8%
Total Income72.7912.2%91.8%
Expenditure112.7813.8%5.1%
PBT—
Net Profit-49.3615.7%31.3%
OPM-54.95%2.22pp
NPM-67.82%2.03pp
EPS-0.5514.6%33.7%
View full financials

Syndax Pharmaceuticals Reports Strong Second Quarter 2026 Financial Results and Provides Business Update

05 Aug 2026 · 5 Aug, 1:39 am

Summary

Syndax Pharmaceuticals reported strong second quarter 2026 financial results, with total revenue surging 92% year-over-year to $72.8 million. This growth was driven by significant increases in net revenue for both Revuforj® (up 91% YoY to $54.7 million) and Niktimvo™ (up 67% YoY to $60.3 million, contributing $18.1 million in collaboration revenue). The company also highlighted pipeline advancements, including two new assets with first- and best-in-class potential, and anticipates key data readouts in the fourth quarter of 2026. With $575.1 million in cash, Syndax is well-funded to advance its strategic priorities and is driving towards profitability.

Key Highlights

  1. 1

    Total revenue for Syndax reached $72.8 million in the second quarter of 2026, marking a significant 92% year-over-year increase.

  2. 2

    Revuforj® (revumenib) achieved $54.7 million in net revenue in 2Q26, representing a 91% year-over-year increase and the sixth consecutive quarter of double-digit net revenue growth.

  3. 3

    Niktimvo™ (axatilimab-csfr) generated $60.3 million in net revenue in 2Q26, a 67% year-over-year increase, contributing $18.1 million in collaboration revenue to Syndax.

  4. 4

    The company expanded its pipeline with two new assets: a novel, mutant-selective, allosteric EGFR inhibitor for NSCLC and a next-generation menin inhibitor for myelofibrosis.

  5. 5

    Topline data from Phase 2 trials of axatilimab in IPF and frontline cGVHD are expected in the fourth quarter of 2026.

  6. 6

    Syndax reported $575.1 million in cash, cash equivalents, and investments as of June 30, 2026, providing ample funding for strategic priorities.

Management Comments

M

Michael A. Metzger

We delivered another quarter of strong commercial results, with both our medicines now annualizing at well over $200 million each and positioned for further growth. Notably, we achieved $55 million in Revuforj net revenue and the sixth consecutive quarter of double-digit net revenue and prescription growth, highlighting our leadership in menin inhibition, robust demand in both NPM1 and KMT2A, and an increasing average treatment duration. Niktimvo net revenue grew to $60 million this quarter, underscoring the benefits of its unique mechanism of action in cGVHD and the substantial commercial opportunity. We’ve made excellent progress advancing our growing pipeline targeting multiple blockbuster opportunities, including two recently announced assets with first- and best-in-class potential in EGFR-mutated NSCLC and myelofibrosis. We are positioned to be first to frontline AML with Revuforj, driven by strong global site initiation and patient enrollment in our pivotal trials. We also have multiple near-term catalysts with Niktimvo Phase 2 data in IPF and frontline cGVHD expected in the fourth quarter, plus additional practice-informing and potentially guideline-enabling Revuforj data in acute leukemia.

Informational and educational content only. Not investment advice.